Savage William Jacob

CMO William Jacob Savage sells 13,093 shares at $91.22 avg; 100% success rate timing prior IRON sales, as unprofitable company flirts with 52-week highs.

William Jacob Savage, Chief Medical Officer of Disc Medicine (IRON), executed 3 separate sales totaling 13,093 shares for $1,194,372.11 on 2025-12-15, reducing his holdings by 14.7% to 75,702 shares. The sales occurred near the company's 52-week high of $94.11 (current price $91.47, only -2.8% from peak), at a blended average price of $91.22. Notably, Savage's 5 prior open-market sales at IRON all generated negative 90-day returns (ranging from -9.1% to -18.6%), establishing a perfect 100% timing pattern on this ticker. His cross-ticker track record shows a 100.00% well-timed sell rate, though with mixed 90-day outcomes (avg +3.2% 30-day, avg -13.8% 90-day). The sale occurs against a backdrop of company fundamentals showing negative $62,321,000 net income for the most recent full fiscal year, yet a substantial $3.5B market cap—a contrasting signal that invites scrutiny of the CMO's conviction at current valuations.

CMO Savage sells 14,183 shares (26.0% of holdings) for $928,326.48 at blended average $65.45; stock now -16.8% from 52-week high.

Savage William Jacob, Chief Medical Officer of Disc Medicine, executed 3 separate sales totaling 14,183 shares on 2024-11-25, reducing his holdings by 26.0% from 54,588 to 40,405 shares. The blended average sale price of $65.45 exceeds the current price of $62.65, though the stock has rebounded 36.2% over the past 30 days and 26.6% over 90 days following steep declines from its 52-week high of $75.32. The company is unprofitable with a net loss of $-26,599,000.00 over its most recent full fiscal year. The timing context is limited: Savage executed a similar series of 3 separate sales on 2024-11-15 (just 10 days prior), indicating a pattern of deliberate liquidation that warrants monitoring given the company's unprofitability and the magnitude of holdings reduction.

CMO William Jacob Savage sells 9,158 shares at blended $59.64, reducing stake by 18.5% to 40,405 shares at IRON

Chief Medical Officer William Jacob Savage executed 3 separate sales totaling 9,158 shares for $546,152.61 on 2024-11-15, reducing his position from 49,563 shares to 40,405 shares—an 18.5% reduction in holdings. The sales occurred at prices ($59.54, $60.16, $61.10) near the current market price of $59.55, within the 52-week range of $26.52–$75.32 and representing a -20.9% discount from the 52-week high. Disc Medicine remains unprofitable with full-year net income of $-26,599,000.00, a material context for executive liquidity activity. The substantial reduction in the CMO's direct ownership stake warrants investor attention given the company's negative earnings and the magnitude of the divestiture relative to pre-transaction holdings.